01.04.2010 • News

Dow Chemical CEO Pay Up 16% for 2009

Andrew Liveris
Andrew Liveris

Dow Chemical Chief Executive Andrew Liveris' total compensation jumped 16% for 2009, when the chemical maker bought rival Rohm & Haas and its stock nearly doubled, according to filings with the U.S. Securities and Exchange Commission.

Liveris, who is also chairman of the board, made $18,279,792 in total compensation for 2009, compared with $15,704,585 for 2008, as reported by the company. The tally includes salary, bonus, the cost of stock and option awards that vested during the year, nonequity incentive pay, change in pension value and nonqualified deferred compensation earnings, and other items.

The tally may vary when calculated by pay consultants and corporate governance experts. There is disagreement on whether the SEC-mandated tally obscures what an executive was actually awarded because it counts stock and options as part of total pay when they vest rather than when they are awarded.

Liveris' stock awards increased for 2009 increased to $6.92 million, but his option awards fell to $2.36 million. Much of Liveris' total compensation increase was due to a performance bonus of $4.49 million. He did not receive a performance bonus in 2008. Liveris received $22,154 for a company car, $138,296 for a company airplane, and $62,345 in financial planning assistance.

The value of his pension fell 10.6% to $2.61 million, and his base salary rose less than 1% to $1.65 million. Shares of Midland, Michigan-based Dow jumped 83% in 2009. The company bought rival chemical maker Rohm & Haas on April 1, 2009, for more than $15 billion and spent the year selling off assets to pay for the deal and integrating Rohm's vast assets. Dow's revenue rose 15% in 2009 to $12.47 billion. It posted net income of $87 million compared with a net loss of $1.55 billion in 2008.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read